Abstract:409 Background: The X-ray repair cross-complementing protein 1 (XRCC1) gene plays an important role in DNA damage repair; and the R194W and R399Q single nucleotide polymorphisms (SNPs) are associated with attenuated DNA repair activity. Our objective was to determine whether XRCC1 SNPs were associated with response to neoadjuvant chemoradiation therapy (CRT) in rectal cancer patients. Methods: We conducted a prospective multicenter phase II trial to investigate the effect of additional chemotherapy with a longer CRT-to-surgery interval on treatment response in patients with rectal cancer. Paired normal and rectal cancer tissues were prospectively collected from enrolled patients (n=110). DNA was extracted from normal rectal mucosa and analyzed for XRCC1 R194W and R399Q by polymerase chain reaction and sequencing. Each SNP was compared to response to CRT. Response to CRT was determined by a central pathologist. Results: Of the 110 patients, 25% (n=27) achieved a pathologic complete response (pCR). We examined the XRCC1 R194W SNP and observed that the allelic frequency of patients with the R/R genotype was 84% (n=92), the R/W genotype was 14% (n=16), the W/W genotype was 1% (n=2). By Fisher's Exact test, patients harboring either the R/W or W/W genotype, had a significantly higher rate of pCR compared to patients with the R/R genotype (44% vs. 21%, respectively; p=0.04). We then examined the R399Q SNP and observed that the allelic frequency of patients with the R/R genotype was 34% (n=37), the R/Q genotype was 49% (n=54), and the Q/Q genotype was 17% (n=19). In contrast, the detection of XRCC1 R399Q SNPs was not associated with pCR. Conclusions: We demonstrate that XRCC1 R194W SNP is associated with increased rate of pCR in our prospective multi-center trial. Although the detection of XRCC1 R399Q SNP is not associated with pCR, the detection of XRCC1 SNPs that predict treatment response may help identify patients who are unlikely to respond to CRT and therefore may potentially avoid treatment-associated morbidities. No significant financial relationships to disclose.

Gene Polymorphisms Predict Toxicity to Neoadjuvant Therapy in Patients with Rectal Cancer

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Use Of Genetic Variations To Predict Toxicity Associated With Neoadjuvant Chemoradiation For Ajcc Stage Ii/Iii Rectal Cancer.

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

P5-19-07: the Effects of ABCC2 and SLCO1B3 Single Nucleotide Polymorphisms on Docetaxel-Induced Leukopenia in Breast Cancer Patients.

Genetic Polymorphisms in Genes Regulating Cell Death and Prognosis of Patients with Rectal Cancer Receiving Postoperative Chemoradiotherapy

Relationship Between Single Nucleotide Polymorphisms and the Toxicy and Side Effects of Paclitaxel and Platinum-Based Chemotherapy in Patients with Malignant Tumors

Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

Association of common polymorphisms in p 53 and MDM 2 with platinum-related grade III / IV toxicities in Chinese advanced lung adenocarcinoma patients

DNA Repair Gene Polymorphisms Do Not Predict Response to Radiotherapy-Based Multimodality Treatment of Patients with Rectal Cancer: a Meta-Analysis.

Association of MDR1 and ERCC1 Polymorphisms with Response and Toxicity to Cisplatin-Based Chemotherapy in Non-Small-cell Lung Cancer Patients.

Genetic Polymorphisms and Platinum-Based Chemotherapy-Induced Toxicities in Patients With Lung Cancer: A Systematic Review and Meta-Analysis.

Genetic Polymorphisms in MicroRNA-related Genes As Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients.

Associations of Genetic Variations in MicroRNA Seed Regions With Acute Adverse Events and Survival in Patients With Rectal Cancer Receiving Postoperative Chemoradiation Therapy.

Programmed Death-Ligand 1 Single Nucleotide Polymorphism Affects Breast Cancer Chemosensitivity and Adverse Events in the Neoadjuvant Setting

Use of the XRCC1 Single Nucleotide Polymorphism to Predict Pathologic Complete Response to Neoadjuvant Chemoradiation in Stage II/III Rectal Cancer.

The impact of EGFR gene polymorphisms on the response and toxicity derived from neoadjuvant chemotherapy for breast cancer.

Genetic Polymorphisms of PAI-1 and PAR-1 Are Associated with Acute Normal Tissue Toxicity in Chinese Rectal Cancer Patients Treated with Pelvic Radiotherapy.

Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer

Machine Learning for Genetic Prediction of Chemotherapy Toxicity in Cervical Cancer.